Bridging the innovation gap: Scalable cell therapies, adaptive trials, and the business of late-stage oncology

Over the past decade, immuno-oncology proved a crucial point: given the right direction, the human immune system can recognise and destroy cancer cells. Therapies like checkpoint inhibitors and first-generation CAR-T cells transformed how we think about treatment. But as these early approaches have matured, their practical and biological limits have become clear.

Custom autologous cell therapies face immense manufacturing bottlenecks, steep financial costs, and vein-to-vein logistical friction. At the same time, solid tumours, which account for approximately 90% of adult cancers globally, continue to present formidable microenvironments that block systemic immune entry and resist traditional single-agent approaches.

To deliver on the promise of modern oncology, the biotechnology sector must engineer therapies that outsmart complex solid tumours while simultaneously building manufacturing and trial models that make those treatments scalable, accessible, and commercially viable. Overcoming these barriers requires rethinking how we manufacture cellular medicines, how we design late-stage clinical trials for heavily pretreated patients, and how we navigate the difficult financial transition from early discovery to Phase 3 registration studies.

The paradigm shift: From bespoke to off-the-shelf cell platforms

The first wave of cell therapy proved the concept of living drugs, but its bespoke nature created an inherently limited delivery model. Autologous therapies require harvesting a patient's own immune cells, shipping them to a specialised facility, genetically modifying them, expanding them over several weeks, and shipping them back for reinfusion.

For patients with rapidly progressing, late-stage solid tumours, every single day matters and this turnaround time is too long. Beyond time constraints, the extreme cost of custom manufacturing creates a severe economic strain on healthcare systems and limits broad patient access.

The future of cellular oncology lies in off-the-shelf, targeted platforms. Off-the-shelf strategies utilise pre-manufactured cell lines that can be stored at treatment facilities and administered immediately upon diagnosis or disease progression. By shifting away from individualised patient manufacturing towards off-the-shelf cell banking models, modern platforms drastically reduce production costs, lower health system burdens, and eliminate critical treatment delays.

When physicians can identify a patient's tissue type from a simple saliva swab and match them to an off-the-shelf cell line, precision oncology becomes truly practical. Patients get targeted therapy right away, while health systems avoid the immense logistical and financial strain of custom manufacturing.

Targeting the unreachable: Next-generation immunotherapies in solid tumours

While haematologic malignancies have responded remarkably well to single-target cell therapies, solid tumours present a far more hostile landscape. Advanced solid tumours, such as metastatic breast cancer, actively construct immunosuppressive microenvironments, secrete inhibitory cytokines, downregulate antigen expression, and physically block immune infiltration. As a result, many solid tumours remain immunologically "cold", preventing active T-cells from mounting an effective attack.

To penetrate these complex environments, next-generation immunotherapies are moving toward multi-faceted mechanisms of action. Rather than relying on a single pathway or a single engineered T-cell receptor, modern whole-cell and platform approaches aim to induce broad, dual immune activation.

By genetically modifying platforms to secrete immune-stimulating factors such as Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and actively presenting multiple tumour targets directly to the immune system, targeted cell platforms can stimulate both CD4+ helper and CD8+ cytotoxic T-cells. This comprehensive stimulation helps convert "cold" immunosuppressive tumours into "hot" targets, priming native immune cells to attack heterogeneous tumour populations and overcome therapeutic resistance to standard regimens like immune checkpoint blockade or antibody-drug conjugates (ADCs).

Redesigning late-stage clinical trials for refractory patients

Developing novel immunotherapies for advanced-stage solid tumours requires a realistic approach to clinical trial design. Patients entering late-stage trials have typically exhausted multiple standard-of-care options, including traditional chemotherapy, radiation, and frontline targeted therapies. Their immune systems are often depleted from prior cytotoxic treatments, and their tumours have been selected for aggressive immune evasion and central nervous system (CNS) metastases.

Running successful trials in heavily pretreated patients requires moving past rigid, outdated protocol structures. Modern late-stage designs need flexible protocols that adapt as data comes in, broader enrolment criteria that reflect real-world patients, and practical control groups that accurately measure success.

Adaptive trial protocols allow for real-time adjustments based on interim safety and efficacy signals, enabling researchers to optimise dosing, patient stratification, and cohort expansion without halting ongoing studies. Moving beyond simple genomic sequencing, trial designs must evaluate immune profiling, tissue-type matching, cytokine dynamics, and microenvironment characteristics to identify patient subgroups most likely to achieve durable responses.

Furthermore, because single-agent interventions rarely overcome complex resistance in advanced disease, late-stage protocols are increasingly evaluating rational combinations that pair novel cellular immunotherapies with established checkpoint inhibitors.

Streamlining the path from early clinical signal to Phase 3 registration

Even the most promising scientific breakthroughs face significant headwinds in the commercial and regulatory marketplace. The transition from early-stage discovery to registration-enabling Phase 3 trials is often referred to as the biotech industry's "valley of death". In oncology, this bridge is particularly difficult to cross due to escalating capital requirements, complex regulatory demands, and changing competitive standards.

To successfully navigate this translation, biotech companies must align their early clinical strategies with late-stage commercial realities. Addressing escalating capital costs requires prioritising off-the-shelf platform technologies early, demonstrating clear economic viability to investors, payors, and commercial partners prior to costly Phase 3 trials.

Managing regulatory interactions demands early engagement with agencies and leveraging programmes like the FDA’s Fast Track Designation to establish validated surrogate endpoints, clear biomarker stratifications, and robust safety profiles tailored to advanced patient populations. Finally, to prevent costly manufacturing delays during late-stage trials and commercial rollout, companies must ensure that early-phase manufacturing processes are fully standardised, repeatable, and scalable across global clinical site networks.

Strategic collaboration is vital to sustaining this pipeline. Partnerships between emerging biotech innovators, academic centres, health systems, and regulatory bodies help pool resources, mitigate financial risk, and accelerate the delivery of novel therapies to patients who have exhausted standard choices.

A scalable future for cancer care

The ultimate success of cancer immunotherapy will not be measured solely by isolated clinical breakthroughs, but by our ability to make highly effective, targeted treatments widely accessible. By shifting towards off-the-shelf cellular platforms, engineering multi-targeted approaches for solid tumours, modernising late-stage clinical trials, and proactively addressing the commercial challenges of drug development, the biotech industry can forge a more efficient path from concept to patient care.

The immune system remains our most powerful weapon against cancer. As science, clinical strategy, and manufacturing capabilities continue to align, we move closer to a reality where advanced, personalised immuno-oncology is no longer a rare exception, but a scalable, standard option for patients facing the most challenging diagnoses.

About the author

William V. Williams, MD, FACP, is president & CEO of BriaCell Therapeutics Corp. Dr Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr Williams has served as BriaCell’s president & CEO since November 2016. He earned his BSc in Chemistry and Biotechnology from MIT and Medical Doctorate from Tufts University School of Medicine. At the University of Pennsylvania, he developed novel methods of bioactive peptide design, ran a major research programme in receptor biology, collaborated in the development of DNA vaccines, and introduced novel therapies into the clinic. At GlaxoSmithKline, he brought several molecules into the clinic, ran an international biomarker laboratory, spearheaded the application of emerging technologies to drug development, and worked on regulatory approvals for drugs. At Incyte Corporation, he established proof of concept for drugs in several disease areas including cancer, rheumatoid arthritis, psoriasis, and diabetes. Dr Williams is the named author at over 130 peer-reviewed publications, over 15 patents, and numerous Investigational New Drugs (INDs) and NDAs.